Takeda-Zydus Enter Increasingly Crowded Chikungunya Fray
Executive Summary
Takeda and Zydus Cadila are stepping into the fray to develop a vaccine for chikungunya, an increasingly crowded segment that now has over a dozen candidates in various stages of development.
You may also be interested in...
Takeda Introduces Vedolizumab In India Amid Signs Of Gear Shift
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
Deal Watch, Focus On Acquisitions: Emergent Acquires PaxVax, Pair Of Commercialized Vaccines
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.
Takeda-Shire In India: Sleeping Giant?
Will Takeda take a less measured approach in India, where Shire brings it a significant on-market portfolio? Scrip outlines the current shape of things in the promising but complex emerging market as the two companies head towards combining forces globally.